Eye problems in breast cancer patients treated with tamoxifen


Background:Tamoxifen is an oral anti-estrogen used in the treatment of breast cancer and recently approved to reduce the incidence of breast cancer in high risk women. As a large clinical trial of tamoxifen has reported an increased risk of cataract, we conducted a study of women with breast cancer to evaluate the association of tamoxifen with cataracts and other eye problems.

Methods:We attempted to recruit previously interviewed patients who were cases in a population-based case-control study of 2653 women with primary breast cancer diagnosed between 1987 and 1996 at ages 55–72 years in Los Angeles County, California, USA. In November 1997, each case was mailed a questionnaire to ascertain self-reported incidence of eye diseases and Amsler grid test scores. Information from 1297 women aged 57–75 years of age was analyzed. Women reporting treatment with tamoxifen were categorized as standard-term users (4–5 years), short-term users (<4 years), or long-term users (6+ years) and compared to non-users. All p-values, relative risks, and confidence intervals for differences in eye problems and grid test results are adjusted for age and stage of disease at diagnosis.

Findings:Standard-term and long-term users of tamoxifen more frequently reported developing cataracts than non-users (18.2%, 21.4% vs. 14.8%). The relative risk was 1.40 (95% confidence interval 0.94–2.10) for standard-term users and 1.70 (1.11–2.59) for long-term users. Tamoxifen use was unrelated to frequency of glaucoma or macular degeneration or to Amsler grid test results.

Interpretation:Our study suggests that five or more years of tamoxifen use increases risk of cataracts. Healthy women considering tamoxifen use to reduce risk of breast cancer should be advised of the possibility of cataract development. Women choosing such therapy should be diligent about receiving regular ocular exams.

This is a preview of subscription content, access via your institution.


  1. 1.

    Forbes JF: The control of breast cancer: The role of tamoxifen. Seminars in Oncology 24 (Supple 1): S1–5–S1–19, 1997

    Google Scholar 

  2. 2.

    Fisher B, Costantino JP, Wickerman DL, et al: Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90: 1371–1388, 1998

    Google Scholar 

  3. 3.

    Kaiser-Kupfer MI, Lippman ME: Tamoxifen retinopathy. Cancer Treat Rep 62: 315–320, 1978

    Google Scholar 

  4. 4.

    Nayfield SG, Gorin MB: Tamoxifen-associated eye disease: A review. J Clln Oncol 14: 1018–1026, 1996

    Google Scholar 

  5. 5.

    Ross RK, Paganini-Hill A, Wan PC, Pike MC: Effect of hormone replacement therapy on breast cancer risk: Estrogen versus estrogen–progestin. J Natl Cancer Inst (In press)

  6. 6.

    Breslow NE, Day NE: Statistical Methods in Cancer Research. Lyon, France, International Agency for Research on Cancer, 1987

    Google Scholar 

  7. 7.

    Gorin MB, Day R, Costantino JP, et al: Long-term tamoxifen citrate use and potential ocular toxicity. Am J Ophthalmol 125: 493–501, 1998

    Google Scholar 

  8. 8.

    Greaves P, Goonetilleke R, Nunn G, Topham J, Orton T: Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res 53: 3919–3924, 1993

    Google Scholar 

  9. 9.

    Zhang JJ, Jacob TJC, Valverde MA, et al: Tamoxifen blocks chloride channels. A possible mechanism for cataract formation. J Clin Invest 94: 1690–1697, 1994

    Google Scholar 

  10. 10.

    Tolentino MJ, Miller S, Gaudio AR, Sandberg MA: Visual field deficits in early age-related macular degeneration. Vision Res 34: 409–413, 1994

    Google Scholar 

  11. 11.

    Ariyasu RG, Lee PP, Linton KP, et al: Sensitivity, specificity, and predictive values of screening tests for eye conditions in a clinic-based population. Ophthalmology 103: 1751–1760, 1996

    Google Scholar 

Download references

Author information



Rights and permissions

Reprints and Permissions

About this article

Cite this article

Paganini-Hill, A., Clark, L.J. Eye problems in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat 60, 167–172 (2000). https://doi.org/10.1023/A:1006342300291

Download citation

  • Amsler grid
  • cataract
  • eye problems
  • glaucoma
  • macular degeneration
  • tamoxifen